Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease

TARRYTOWN, N.Y. and PARIS, Oct. 25, 2021 /PRNewswire/ -- Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial Eosinophilic esophagitis is a progressive...

from PR Newswire: https://ift.tt/3puNvQt